FADILA HAYA DZUARY, - (2024) ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN MORFIN DAN FENTANIL PADA PASIEN KANKER PAYUDARA DALAM PENATALAKSANAAN NYERI DI RUMAH SAKIT “X” KOTA BANDUNG. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
Text
S_PSSF_A223001_Title.pdf Download (509kB) |
|
Text
S_PSSF_A223001_Chapter1.pdf Restricted to Repository staff only Download (121kB) |
|
Text
S_PSSF_A223001_Chapter2.pdf Restricted to Repository staff only Download (592kB) |
|
Text
S_PSSF_A223001_Chapter3.pdf Restricted to Repository staff only Download (229kB) |
|
Text
S_PSSF_A223001_Chapter4.pdf Restricted to Repository staff only Download (354kB) |
|
Text
S_PSSF_A223001_Chapter5.pdf Restricted to Repository staff only Download (33kB) |
|
Text
S_PSSF_A223001_Appendix.pdf Restricted to Repository staff only Download (2MB) |
Abstract
Kanker payudara menduduki peringkat pertama dalam jumlah kasus kanker di Indonesia pada tahun 2022. Keluhan yang umum dirasakan oleh pasien kanker adalah nyeri yang mana hal ini dapat mengganggu kenyamanan hidup pasien. Penatalaksanaan nyeri pada pasien kanker merupakan perawatan jangka panjang yang memerlukan perhatian dan biaya yang lumayan besar, sehingga perlu dilakukannya suatu analisis farmakoekonomi untuk memperoleh pilihan terapi yang paling cost-effectiveness. Penelitian ini bertujuan untuk mengetahui pengobatan nyeri yang paling cost-effectiveness serta aman antara obat morfin dan fentanil pada pada pasien kanker payudara di rumah sakit “X” kota Bandung periode November 2022 – April 2024. Penelitian ini dilakukan dengan metode observasional retrospektif, menggunakan data rekam medis dan data keuangan pasien. Pengambilan sampel dilakukan secara purposive non-random sampling dengan pendekatan total sampling, berdasarkan kriteria inklusi dan eksklusi yang telah ditetapkan. Hasil penelitian menunjukkan bahwa penggunaan fentanil (Durogesic®) merupakan pilihan yang paling cost-effectiveness dengan nilai ACER sebesar Rp 9.685 dibandingkan morfin (MST Continus®) yang memiliki nilai ACER Rp 28.351. Selain itu, fentanil (Durogesic®) lebih aman dengan persentase pasien yang tidak membutuhkan terapi efek samping sebesar 38,46%, dibanding morfin (MST Continus®) dengan persentase sebesar 27,78%. ----- Breast cancer ranked first in the number of cancer cases in Indonesia in 2022. A common complaint experienced by cancer patients is pain, which can disrupt the patients quality of life. Pain management in cancer patients is a long-term treatment that requires significant attention and substantial costs, making it necessary to conduct a pharmacoeconomic analysis to obtain the most costeffectiveness therapy option. This study aims to identify the most cost-effectiveness and safe pain between morphine and fentanyl for breast cancer patients at Hospital "X" in Bandung from November 2022 to April 2024. This research was conducted using a retrospective observational method, utilizing patients medical records and financial data. Sampling was carried out through purposive non-random sampling with a total sampling approach based on predetermined inclusion and exclusion criteria. The results showed that the use of fentanyl (Durogesic®) was the most cost-effective option with an ACER value of IDR 9,685 compared to morphine (MST Continus®) with an ACER value of IDR 28,351. Additionally, fentanyl (Durogesic®) was safer, with 38.46% of patients not requiring side effect therapy, compared to morphine (MST Continus®) with 27.78%.
Item Type: | Thesis (Skripsi) |
---|---|
Uncontrolled Keywords: | Kanker payudara, nyeri kanker, cost-effectiveness analysis, fentanil (Durogesic®), morfin (MST Continus®). ----- Breast cancer, cancer pain, cost-effectiveness analysis, fentanyl (Durogesic®), morphine (MST Continus®) |
Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine |
Divisions: | Program Studi S1 Farmasi |
Depositing User: | pustakawan - - |
Date Deposited: | 28 Aug 2024 02:12 |
Last Modified: | 28 Aug 2024 02:12 |
URI: | http://repository.stfi.ac.id/id/eprint/1078 |
Actions (login required)
View Item |